UCB Biosciences Inc.

FDA Regulatory Profile

UCB Biosciences Inc. appears in FDA public data with 1 recall, 0 510(k) clearances, 5 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0546-2026, Class II) was initiated on May 8, 2026.

Summary

Total Recalls
1
510(k) Clearances
0
Inspections
5
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-0546-2026Class IIcimzia (certolizumab pegol), 2x200mg/mL PREFILLED SYRINGES (2 single-dose), Rx ONLY, Manufactured byMay 8, 2026